Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “inventing” anything. They’re extending.
In pharma, the most consequential moves rarely look like breakthroughs. They look like paperwork—amendments, new claims, fresh filings, and carefully timed patent strategies that keep a p…

Most biosimilar strategies fail for one reason: they show up too late.
In biosimilars, timing isn’t a “nice-to-have.” It’s the whole game.
Right now, manufacturers are making equipment and capacity decisions—often months (or longer) before the market a…

Drug patent protection in Europe: how long it lasts—and where it quietly breaks down
Most people think European drug patents are a simple clock: file today, expire later. In reality, the timeline is a patchwork—extended by legal mechanisms, interrupted…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Market Access Teams Can Stop Getting Blindsided.
If you work in commercial market access, you’ve probably felt it: the sudden scramble when a blockbuster’s exclu…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
In the patent world, “winning” is often treated like a finish line. But for first filers, the real story starts after the courtroom—when the market decides whether your excl…

The clock is ticking—and “true generic” timing is where deals are won or lost.
In pharma, everyone talks about exclusivity. Fewer people map it with the precision required to hit the market window for a true generic entry—especially when multiple regul…